Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study

@inproceedings{Gor2009CyclophosphamideME,
  title={Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study},
  author={Priya P Gor and H. Irene Su and Robert J. Gray and Phyllis A. Gimotty and Michelle Horn and Richard Aplenc and William P. Vaughan and Martin S. Tallman and Timothy R. Rebbeck and Angela DeMichele},
  booktitle={Breast Cancer Research},
  year={2009}
}
Cyclophosphamide-based adjuvant chemotherapy is a mainstay of treatment for women with node-positive breast cancer, but is not universally effective in preventing recurrence. Pharmacogenetic variability in drug metabolism is one possible mechanism of treatment failure. We hypothesize that functional single nucleotide polymorphisms (SNPs) in drug metabolizing enzymes (DMEs) that activate (CYPs) or metabolize (GSTs) cyclophosphamide account for some of the observed variability in disease outcomes… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…